Literature DB >> 19671849

Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?

Serena Di Cosimo1, José Baselga.   

Abstract

Gain-of-function mutations in the catalytic subunit of phosphoinositide-3-kinase (PI3KCA) occur frequently in breast cancer. Kalinsky and colleagues show that PI3KCA mutations are associated with favorable clinicopathologic features and better clinical outcome, including survival. These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19671849     DOI： 10.1158/1078-0432.CCR-09-1173

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  16 in total

1.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Authors:  Sherene Loi; Benjamin Haibe-Kains; Samira Majjaj; Francoise Lallemand; Virginie Durbecq; Denis Larsimont; Ana M Gonzalez-Angulo; Lajos Pusztai; W Fraser Symmans; Alberto Bardelli; Paul Ellis; Andrew N J Tutt; Cheryl E Gillett; Bryan T Hennessy; Gordon B Mills; Wayne A Phillips; Martine J Piccart; Terence P Speed; Grant A McArthur; Christos Sotiriou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 2.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Authors:  Lucia Veronica Cuorvo; Paolo Verderio; Chiara Maura Ciniselli; Salvatore Girlando; Nicola Decarli; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Claudio Eccher; Chiara Cantaloni; Francesco Mauri; Michael Seckl; Marco Volante; Fiamma Buttitta; Antonio Marchetti; Quattrone Silvia; Enzo Galligioni; Paolo Dalla Palma; Mattia Barbareschi
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

Review 4.  Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Authors:  Xiaoyong Fu; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2013-09-05       Impact factor: 4.380

5.  Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach.

Authors:  Hezha O Rasul; Bakhtyar K Aziz; Dlzar D Ghafour; Arif Kivrak
Journal:  Mol Divers       Date:  2022-06-23       Impact factor: 2.943

6.  Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

Authors:  Matthew J Ellis; Li Lin; Robert Crowder; Yu Tao; Jeremy Hoog; Jacqueline Snider; Sherri Davies; Katherine DeSchryver; Dean B Evans; Jutta Steinseifer; Raj Bandaru; WeiHua Liu; Humphrey Gardner; Vladimir Semiglazov; Mark Watson; Kelly Hunt; John Olson; José Baselga
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

7.  Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.

Authors:  Andrew Sewell; Brandee Brown; Asel Biktasova; Gordon B Mills; Yiling Lu; Darren R Tyson; Natalia Issaeva; Wendell G Yarbrough
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531

8.  Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Authors:  Raphaëlle Duprez; Paul M Wilkerson; Magali Lacroix-Triki; Maryou B Lambros; Alan MacKay; Roger A'Hern; Arnaud Gauthier; Vidya Pawar; Pierre-Emanuel Colombo; Frances Daley; Rachael Natrajan; Eric Ward; Gaëtan MacGrogan; Flavie Arbion; Patrick Michenet; Britta Weigelt; Anne Vincent-Salomon; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2011-12-09       Impact factor: 7.996

9.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Authors:  Lucia Hernandez; Paul M Wilkerson; Maryou B Lambros; Adriana Campion-Flora; Daniel Nava Rodrigues; Arnaud Gauthier; Cecilia Cabral; Vidya Pawar; Alan Mackay; Roger A'Hern; Caterina Marchiò; Jose Palacios; Rachael Natrajan; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

10.  Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.

Authors:  Carmen Criscitiello; Debora Fumagalli; Kamal S Saini; Sherene Loi
Journal:  Onco Targets Ther       Date:  2010-12-17       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.